Last reviewed · How we verify

Fumarate, Tenofovir Disoproxil

ANRS, Emerging Infectious Diseases · FDA-approved active Small molecule Quality 5/100

Fumarate, Tenofovir Disoproxil is a Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently FDA-approved. Also known as: TDF.

At a glance

Generic nameFumarate, Tenofovir Disoproxil
Also known asTDF
SponsorANRS, Emerging Infectious Diseases
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fumarate, Tenofovir Disoproxil

What is Fumarate, Tenofovir Disoproxil?

Fumarate, Tenofovir Disoproxil is a Small molecule drug developed by ANRS, Emerging Infectious Diseases.

Who makes Fumarate, Tenofovir Disoproxil?

Fumarate, Tenofovir Disoproxil is developed and marketed by ANRS, Emerging Infectious Diseases (see full ANRS, Emerging Infectious Diseases pipeline at /company/anrs-emerging-infectious-diseases).

Is Fumarate, Tenofovir Disoproxil also known as anything else?

Fumarate, Tenofovir Disoproxil is also known as TDF.

What development phase is Fumarate, Tenofovir Disoproxil in?

Fumarate, Tenofovir Disoproxil is FDA-approved (marketed).

Related